

Correction

# Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. *Cancers* 2022, 14, 374

Simon Bailey <sup>1,2,\*</sup>, Nicolas André <sup>3,4,†</sup>, Lorenza Gandola <sup>5,†</sup>, Maura Massimino <sup>6,‡</sup>, Keith Wheatley <sup>7</sup>, Simon Gates <sup>7</sup>, Victoria Homer <sup>7</sup>, Stefan Rutkowski <sup>8,‡</sup> and Steven C. Clifford <sup>2,‡</sup>

<sup>1</sup> Great North Children's Hospital, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK

<sup>2</sup> Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK; steve.clifford@newcastle.ac.uk

<sup>3</sup> Pediatric Hematology and Oncology Department, Hôpital Pour Enfants de La Timone, AP-HM, 13005 Marseille, France; nicolas.andre@ap-hm.fr

<sup>4</sup> Centre de Recherche en Cancérologie de Marseille, SMARTc Unit, Inserm U1068, Aix Marseille University, 13005 Marseille, France

<sup>5</sup> Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; lorenza.gandola@gmail.com

<sup>6</sup> Pediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; maura.massimino@istitutotumori.mi.it

<sup>7</sup> Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT, UK; k.wheatley@bham.ac.uk (K.W.); s.gates@bham.ac.uk (S.G.); v.s.homer@bham.ac.uk (V.H.)

<sup>8</sup> Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; s.rutkowski@uke.de

\* Correspondence: simon.bailey@ncl.ac.uk; Tel.: +44-1912824068

† These authors contributed equally to this work.

‡ These authors contributed equally to this work.



**Citation:** Bailey, S.; André, N.;

Gandola, L.; Massimino, M.; Wheatley,

K.; Gates, S.; Homer, V.; Rutkowski, S.;

Clifford, S.C. Correction: Bailey et al.

Clinical Trials in High-Risk

Medulloblastoma: Evolution of the

SIOP-Europe HR-MB Trial. *Cancers*

2022, 14, 374. *Cancers* 2024, 16, 1084.

[https://doi.org/10.3390/](https://doi.org/10.3390/cancers16061084)

[cancers16061084](https://doi.org/10.3390/cancers16061084)

Received: 12 January 2024

Accepted: 2 February 2024

Published: 7 March 2024



**Copyright:** © 2024 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the Creative Commons

Attribution (CC BY) license ([https://](https://creativecommons.org/licenses/by/4.0/)

[creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/)

[4.0/](https://creativecommons.org/licenses/by/4.0/)).

## Missing Funding

In the original publication [1], the funder Cancer Research UK, A2524 was not included.

## Addition of Authors

Keith Wheatley, Simon Gates, and Victoria Homer were not included as authors in the original publication. The reason we would like to add the authors is that the statistical element of the trial and the trial design were in a large part done by the statistical authors and the team were necessary for the running of the trial. The corrected Author Contributions Statement appears here.

**Author Contributions:** Conceptualization, S.B., N.A., L.G., M.M., K.W., S.R. and S.C.C.; methodology, K.W., S.G. and V.H.; project administration, S.G. and V.H.; resources, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—original draft preparation, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—review and editing, S.B., N.A., L.G., M.M., S.R. and S.C.C. All authors have read and agreed to the published version of the manuscript.

## Additional Affiliation

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT, UK; k.wheatley@bham.ac.uk (K.W.); s.gates@bham.ac.uk (S.G.); v.s.homer@bham.ac.uk (V.H.)

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

---

## Reference

1. Bailey, S.; André, N.; Gandola, L.; Massimino, M.; Rutkowski, S.; Clifford, S.C. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. *Cancers* **2022**, *14*, 374. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.